Carlos Gonzalez· @DrMedOnco · X·· 3 天前评分90
正文 · 机器翻译
NATALEE OS：未达到正式统计学显著性；该分析为描述性分析（名义 P，无 alpha）。相比之下，monarchE 进行了预先设定的 alpha 控制 OS 分析，并达到了标准。NATALEE：HR 稳定在约 0.80，Δ2.1%，BCSS 提供支持。具有临床意义，但并非确证性结果。#ESMO26 #NATALEE #MonarchE
415 浏览 · 9 赞 · 6 转发 · 0 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.orgNATALEE at 6 years: Ribociclib + NSAI vs NSAI alone in HR+/HER2− early breast cancer: • 6-year OS: 91.86% vs 89.73% • OS HR 0.809 (95% CI 0.661–0.989); nominal 1-sided P=0.019 • Absolute OS benefit: 2.1% • 6-year iDFS: 83.23% vs 77.92% • iDFS HR 0.741 (95% CI 0.646–0.849) • Absolute iDFS benefit: 5.3% Is OS significant? Looking forward to full data .@Timothee_MD @myESMO @OncBrothers @OncoAlert #ESMO26 #BreastCancer #NATALEE在 X 查看被引用的帖子
来源：Carlos Gonzalez · x.com